Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
ArriVent BioPharma, Inc.
AVBP · SEC Filings
website
77
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification,...
Price
14.16
Market Cap
698.2 M
Float
37 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about AVBP
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
ArriVent BioPharma, Inc.
AVBP · SEC Filings
37 M
Float
14.16
Price
698.2 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
NEW
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 9, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 11, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 10, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 11, 2025
News
TYPE
HEADLINE
FILED AT
8-K
NEW
ArriVent BioPharma Reports Third Quarter 2026 Financial Results and Pipeline Updates
Nov 9, 2026
8-K
Phase 1 data show ARR-217 achieved 44.8% response rate in late-line colorectal cancer, with manageable safety and Phase 1b optimization underway
Oct 26, 2026
8-K
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
Oct 19, 2026
8-K
ArriVent Doses First Patient in Phase 1 Trial with ARR-002, a Novel Tetravalent MUC16/NaPi2b Dual Target ADC
Oct 13, 2026
8-K
ArriVent Announces Program Update from Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
Oct 6, 2026
8-K
ArriVent BioPharma Reports Second Quarter 2026 Financial Results and Pipeline Progress
Aug 12, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
[No Baby Shelf]* May 2026 ATM | Offering amount: $250,000,000 | Bank: Jefferies LLC
May 11, 2026
424B5
REGISTERED OFFERING
Jul 2, 2025
424B5
PENDING OFFERING
Jul 1, 2025
424B4
9,722,222 Shares
Jan 26, 2024
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 5, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 3, 2025
S-3ASR
Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 3, 2025
S-8
Registration
Feb 2, 2024
S-1MEF
Registration
Jan 25, 2024
S-1/A
8,333,333 Shares
Jan 23, 2024
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 28, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 28, 2025
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G/A
FMR LLC (Filed by)
Nov 5, 2026
4
LaChapelle Robin (Reporting)
Nov 2, 2026
SCHEDULE 13G
Vivo Opportunity Fund Holdings, L.P. (Filed by)
Oct 13, 2026
SCHEDULE 13D/A
ORBIMED ADVISORS LLC (Filed by)
Oct 8, 2026
SCHEDULE 13G/A
BlackRock, Inc. (Filed by)
Jul 27, 2026
4
Parsey Merdad (Reporting)
Jun 22, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Jan 26, 2024
CORRESP
Form CORRESP - Correspondence
Jan 23, 2024
CORRESP
Form CORRESP - Correspondence
Jan 23, 2024
CORRESP
Form CORRESP - Correspondence
Jan 22, 2024
LETTER
Form UPLOAD - SEC-generated letter
Jan 12, 2024
CORRESP
Form CORRESP - Correspondence
Jan 11, 2024
